This glossary explains key terminology used across the Life Sciences sector’s outsourced development, research, manufacturing, and laboratory-tool ecosystem. It helps executives and practitioners navigate the operational, technical, regulatory, quality, and commercial language of the CDMO/CRO & Life-science Tools Practice.
0–9 A B C D E F G H I J K L M N O P Q R S T U V W X
| 0–9 | |
| 21 CFR Part 11 | Title 21 of the Code of Federal Regulations, Part 11: U.S. requirements governing electronic records and electronic signatures used in regulated activities. Compliance affects laboratory, manufacturing, quality, and clinical systems that replace paper records. |
| A | |
| AAALAC | Association for Assessment and Accreditation of Laboratory Animal Care International: An independent organization that accredits animal-care and use programs. Accreditation is an important qualification for preclinical research providers conducting in vivo studies. |
| ACRO | Association of Clinical Research Organizations: A trade association representing clinical research and technology companies. Its policy work and operating principles influence outsourced clinical development practices. |
| ADA | Anti-Drug Antibody: An immune response against a therapeutic product that bioanalytical laboratories measure during immunogenicity testing. Assay sensitivity, specificity, and drug tolerance can materially affect study interpretation. |
| ADaM | Analysis Data Model: A Clinical Data Interchange Standards Consortium standard for analysis-ready clinical trial datasets. It supports reproducible statistical analyses and regulatory submission review. |
| ADME | Absorption, Distribution, Metabolism, and Excretion: The processes used to characterize how a compound behaves in an organism. Preclinical and bioanalytical providers generate these data to support candidate selection, dosing, and safety assessment. |
| AE | Adverse Event: Any unfavorable medical occurrence in a clinical participant administered a medicinal product, whether or not considered product-related. Accurate collection, coding, and reporting are central clinical research responsibilities. |
| ALCOA+ | Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available: Principles used to evaluate the integrity of regulated records throughout their lifecycle. They guide documentation controls across laboratories, manufacturing operations, and clinical systems. |
| API | Active Pharmaceutical Ingredient: The substance in a drug product that provides its intended pharmacological activity. Its synthesis, characterization, scale-up, and controlled manufacture are core services for many development and manufacturing providers. |
| APR | Annual Product Review: A periodic evaluation of manufacturing and quality data used to confirm process consistency and identify improvement needs. It is the common U.S. term for this required product-level review. |
| APS | Aseptic Process Simulation: A qualification exercise that uses microbiological growth medium to simulate an aseptic manufacturing process. It demonstrates that personnel, equipment, facilities, and procedures can maintain sterility under operating conditions. |
| AQL | Acceptance Quality Limit: A sampling-plan threshold used to determine whether a production lot meets predefined acceptance criteria. It is frequently applied to incoming materials, packaging components, and finished-product inspection. |
| ARRIVE | Animal Research: Reporting of In Vivo Experiments: Reporting guidelines intended to improve the transparency and reproducibility of animal studies. Preclinical research providers use them when designing, documenting, and reporting in vivo work. |
| ASMF | Active Substance Master File: A European regulatory document that allows an active-substance manufacturer to provide confidential manufacturing and control information directly to authorities. It supports marketing applications that reference the supplier’s substance. |
| AUC | Area Under the Curve: A pharmacokinetic measure of total systemic exposure over time. Bioanalytical and clinical research teams use it to compare formulations, doses, and treatment conditions. |
| B | |
| BA | Bioavailability: The rate and extent to which an active substance reaches systemic circulation. Specialized clinical and bioanalytical studies evaluate it during formulation development and regulatory programs. |
| BE | Bioequivalence: A determination that two pharmaceutical products have no significant difference in the rate and extent of absorption under defined conditions. Contract research providers commonly design and execute these comparative studies. |
| BET | Bacterial Endotoxins Test: A compendial test used to detect or quantify endotoxins in drugs, biologics, raw materials, and medical-grade process fluids. It is critical for products and components that must meet pyrogen-control requirements. |
| BFS | Blow-Fill-Seal: An automated process that forms, fills, and seals a container in a continuous operation. It is used for high-volume sterile liquids where contamination control and packaging efficiency are important. |
| BI | Biological Indicator: A standardized preparation of resistant microorganisms used to challenge and monitor sterilization processes. Results provide evidence that a validated cycle delivers the required microbial inactivation. |
| BIMO | Bioresearch Monitoring: The U.S. Food and Drug Administration’s inspection program for regulated research involving human subjects, animals, and laboratory data. Clinical and nonclinical service providers may be inspected for compliance and data integrity. |
| BLI | Bio-Layer Interferometry: A label-free optical technique for measuring biomolecular interactions in real time. Instrument and assay providers use it for binding kinetics, concentration measurements, and screening workflows. |
| BLQ | Below the Limit of Quantification: A result indicating that an analyte is present at a level too low for reliable numerical measurement by the validated method. Treatment of these values can affect pharmacokinetic and statistical analyses. |
| BMR | Batch Manufacturing Record: The controlled record documenting materials, instructions, processing steps, observations, and results for a manufactured batch. Review and approval provide evidence that production followed the authorized process. |
| BOM | Bill of Materials: The structured list of raw materials, components, subassemblies, and quantities required to make a product. Accurate configuration is essential for purchasing, planning, costing, and manufacturing control. |
| BPR | Batch Production Record: The executed documentation for producing and packaging a specific batch. It enables quality review, traceability, deviation assessment, and disposition decisions. |
| BSC | Biological Safety Cabinet: A ventilated enclosure designed to protect personnel, products, or the environment during work with biological materials. Selection, certification, and proper use depend on the cabinet class and intended application. |
| BSL | Biosafety Level: A graded containment designation based on biological risk and required laboratory controls. Facility design, work practices, protective equipment, and access restrictions increase with the assigned level. |
| C | |
| C&Q | Commissioning and Qualification: The planned verification that facilities, utilities, systems, and equipment are correctly installed and operate as intended. It creates documented evidence supporting release for regulated use. |
| CAPA | Corrective and Preventive Action: A quality-system process for investigating problems, correcting causes, and preventing recurrence or occurrence. Effective execution is a major indicator of quality maturity during client and regulatory audits. |
| CCIT | Container Closure Integrity Testing: Testing that demonstrates a package can maintain an effective barrier against microbial ingress, gas, moisture, or leakage. It supports sterile-product development, stability programs, and lifecycle control. |
| CCS | Contamination Control Strategy: A coordinated, risk-based plan covering facilities, equipment, personnel, materials, processes, monitoring, and controls that prevent contamination. It is a central expectation for sterile manufacturing under European requirements. |
| CDA | Confidential Disclosure Agreement: A contract governing the exchange and permitted use of confidential information during evaluation or delivery of outsourced services. It commonly precedes technical due diligence, proposals, and technology transfer. |
| CDASH | Clinical Data Acquisition Standards Harmonization: A Clinical Data Interchange Standards Consortium standard for collecting clinical research data consistently. Standardized collection fields facilitate downstream mapping, analysis, and submission preparation. |
| CDISC | Clinical Data Interchange Standards Consortium: A standards-development organization whose data models support clinical and nonclinical research submissions. Its frameworks help sponsors and service providers structure, exchange, analyze, and archive study data. |
| CDMO | Contract Development and Manufacturing Organization: A provider that performs outsourced pharmaceutical development and manufacturing services. Capabilities may span formulation, analytical development, process scale-up, clinical supply, commercial production, and packaging. |
| CDS | Chromatography Data System: Software used to acquire, process, review, report, and retain chromatography data. Validated configuration, access controls, audit trails, and data governance are essential in regulated laboratories. |
| CE | Capillary Electrophoresis: An analytical separation technique that resolves charged molecules within a narrow capillary under an electric field. It is used for purity, identity, charge-variant, and nucleic-acid analyses. |
| CEP | Certificate of Suitability to the Monographs of the European Pharmacopoeia: A certificate confirming that applicable pharmacopoeial monographs adequately control the quality of a substance from a specified source. It can simplify the active-substance portion of European applications. |
| CFR | Code of Federal Regulations: The codification of U.S. federal agency rules, including requirements governing drugs, laboratories, electronic records, and clinical research. Providers use the applicable titles and parts to design compliant operations. |
| cGMP | Current Good Manufacturing Practice: U.S. requirements for systems, facilities, controls, records, and practices used to manufacture regulated products. The word “current” emphasizes that operations must reflect up-to-date methods and technologies. |
| ChP | Chinese Pharmacopoeia: China’s official compendium of pharmaceutical quality standards. Manufacturers and testing laboratories supplying the Chinese market may need to meet its monographs and general chapters. |
| CIP | Cleaning in Place: Automated cleaning of process equipment and piping without major disassembly. Validated cycles control residues and cross-contamination while reducing manual handling and equipment downtime. |
| CIRB | Central Institutional Review Board: A single ethics review body used by multiple participating clinical sites. Central review can improve consistency and reduce duplicated review effort in multicenter studies. |
| CLIA | Clinical Laboratory Improvement Amendments: U.S. requirements governing laboratories that test human specimens for health assessment, diagnosis, prevention, or treatment. Central laboratories supporting clinical studies may require certification under this framework. |
| CMA | Critical Material Attribute: A physical, chemical, biological, or microbiological property of an input material that must be controlled to ensure desired product quality. Identification supports risk-based development and robust process design. |
| CMC | Chemistry, Manufacturing, and Controls: The regulatory information describing how a product and its ingredients are developed, manufactured, tested, controlled, packaged, and stored. Outsourcing partners generate much of the supporting technical data and documentation. |
| CMMS | Computerized Maintenance Management System: Software used to schedule, document, and analyze preventive and corrective maintenance. It supports equipment reliability, calibration status, spare-parts control, and inspection readiness. |
| CMO | Contract Manufacturing Organization: A company that manufactures products or intermediates for another organization under contract. Unlike a full development-and-manufacturing provider, its engagement may focus primarily on production and packaging. |
| CoA | Certificate of Analysis: A controlled document reporting test results and confirming whether a material or product meets specified requirements. Customers and quality units rely on it for receipt, release, and traceability decisions. |
| COA | Clinical Outcome Assessment: A measure describing how a participant feels, functions, or survives, based on patient, clinician, observer, or performance reporting. Selection and validation affect endpoint quality and regulatory acceptability. |
| CoC | Certificate of Conformance: A supplier document attesting that specified materials or products conform to defined requirements. Quality agreements determine when this certification is sufficient and when supporting test data are required. |
| CoC | Chain of Custody: Documented control of a sample, material, or record as it is collected, transferred, stored, tested, and disposed. It protects identity, traceability, security, and evidentiary integrity. |
| COP | Clean Out of Place: Cleaning performed after equipment parts are removed and transferred to a dedicated cleaning station. Procedures must control disassembly, cleaning parameters, inspection, storage, and reassembly. |
| CPP | Critical Process Parameter: A process variable whose variability can affect a critical quality attribute and therefore requires monitoring or control. Establishing appropriate ranges is central to process understanding and validation. |
| CPV | Continued Process Verification: Ongoing collection and analysis of commercial manufacturing data to confirm that a process remains in a state of control. Trends can trigger investigations, corrective action, or process improvement. |
| CQA | Critical Quality Attribute: A product property that must remain within an appropriate limit, range, or distribution to assure quality. These attributes connect patient or user needs to material controls, process parameters, and specifications. |
| CQV | Commissioning, Qualification, and Validation: An integrated lifecycle approach for demonstrating that facilities, utilities, equipment, systems, and processes are fit for intended use. It is fundamental to bringing new or expanded regulated capacity online. |
| CRA | Clinical Research Associate: A professional who monitors clinical sites and verifies compliance with the protocol, ethical requirements, regulations, and sponsor procedures. The role is central to site oversight and issue escalation. |
| CRC | Clinical Research Coordinator: A site-based professional who manages day-to-day study activities under the principal investigator’s supervision. Responsibilities often include participant coordination, data entry, documentation, and visit preparation. |
| CRF | Case Report Form: The paper or electronic instrument used to capture protocol-required information for each clinical participant. Clear design and completion rules directly affect data quality and query volume. |
| CRO | Contract Research Organization: A provider performing outsourced research services for sponsors. Offerings may include preclinical testing, clinical operations, data management, biostatistics, laboratory services, safety surveillance, and regulatory support. |
| CSR | Clinical Study Report: The integrated report describing a clinical study’s design, conduct, statistical analyses, results, and conclusions. It is a major regulatory deliverable prepared after database lock and analysis. |
| CSV | Computerized System Validation: Documented evidence that a computerized system consistently fulfills its intended use and applicable regulatory requirements. The effort is scaled according to system risk, complexity, and impact on product quality or data integrity. |
| CTA | Clinical Trial Agreement: A contract defining responsibilities, budgets, payment terms, publication rights, indemnification, and other conditions between a sponsor or provider and a study site. Execution is often a critical study-startup dependency. |
| CTA | Clinical Trial Application: A submission requesting authorization to conduct a clinical trial in a jurisdiction. It typically contains protocol, safety, product-quality, investigator, and administrative information. |
| CTCAE | Common Terminology Criteria for Adverse Events: A standardized framework developed by the U.S. National Cancer Institute for naming and grading adverse events. It promotes consistent safety assessment, particularly in oncology research. |
| CTD | Common Technical Document: The harmonized structure used to organize quality, nonclinical, and clinical information in medicinal-product applications. Development and manufacturing partners often supply substantial portions of its quality modules. |
| CTIS | Clinical Trials Information System: The European Union portal and database for clinical trial applications, regulatory review, oversight, and public information. Sponsors and delegated providers use it to manage trials under the European framework. |
| CTMS | Clinical Trial Management System: Software that manages study planning, site information, milestones, monitoring, payments, documents, and operational metrics. It provides portfolio visibility and supports oversight of internal and outsourced work. |
| CTR | Clinical Trials Regulation: The European Union regulation governing authorization and supervision of interventional medicinal-product trials. It establishes coordinated review, transparency, safety, and reporting requirements across member states. |
| D | |
| DBL | Database Lock: The controlled point at which a clinical study database is finalized and further changes are restricted. Lock follows completion of data cleaning, reconciliation, coding, and required approvals. |
| DCS | Distributed Control System: An industrial control platform that monitors and controls manufacturing processes across connected controllers and operator interfaces. Regulated implementations require secure configuration, change control, and reliable data handling. |
| DCT | Decentralized Clinical Trial: A study that performs some or all trial activities away from conventional research sites using remote visits, local services, digital technologies, or direct-to-patient logistics. The model changes oversight, data, and supply requirements. |
| ddPCR | Droplet Digital Polymerase Chain Reaction: A method that partitions samples into many droplets and counts positive reactions for highly sensitive absolute quantification. It is used in nucleic-acid research, assay development, and quality testing. |
| DI | Data Integrity: The completeness, consistency, accuracy, and trustworthiness of data throughout its lifecycle. Controls must address people, processes, instruments, computerized systems, metadata, audit trails, retention, and governance. |
| DLS | Dynamic Light Scattering: An analytical technique used to estimate particle size and distribution from fluctuations in scattered light. It is widely applied to proteins, nanoparticles, colloids, and formulation-development samples. |
| DMC | Data Monitoring Committee: An independent group that periodically reviews accumulating clinical data to assess participant safety, study conduct, and sometimes efficacy. It may recommend continuation, modification, or termination according to a charter. |
| DMF | Drug Master File: A confidential submission containing detailed information about facilities, processes, materials, or components used in pharmaceutical manufacture. Customers can reference it in their applications through authorization from the holder. |
| DMPK | Drug Metabolism and Pharmacokinetics: The discipline examining metabolic fate and drug concentration over time. Outsourced studies inform candidate selection, human-dose projections, interaction risks, and clinical strategy. |
| DoE | Design of Experiments: A statistical approach that varies multiple factors systematically to understand their effects and interactions. It supports efficient method development, formulation optimization, process characterization, and establishment of operating ranges. |
| DP | Drug Product: The finished dosage form containing the active substance and other components, presented for administration. Development and manufacturing responsibilities include formulation, filling, packaging, testing, stability, and release. |
| DQ | Design Qualification: Documented verification that the proposed design of a facility, system, or equipment item is suitable for its intended purpose. It is normally completed before procurement, construction, or installation. |
| DS | Drug Substance: The active material that is subsequently formulated with other ingredients into a finished medicinal product. Manufacturing control includes raw materials, synthesis or processing, purification, characterization, storage, and release. |
| DSMB | Data and Safety Monitoring Board: An independent committee that reviews interim study data to protect participants and assess whether a trial should continue as planned. The term is often used interchangeably with data monitoring committee. |
| DSUR | Development Safety Update Report: A periodic report summarizing and evaluating safety information for an investigational medicinal product. Sponsors and safety-service providers prepare it across active clinical development programs. |
| E | |
| E&L | Extractables and Leachables: Chemical compounds that can be forced from materials under aggressive conditions or migrate into a product under normal use. Assessment is important for packaging, processing equipment, single-use systems, and storage components. |
| eBR | Electronic Batch Record: A digital record that guides and documents manufacturing execution for a batch. Automated checks, electronic signatures, exception handling, and system integration can improve compliance and review efficiency. |
| eCOA | Electronic Clinical Outcome Assessment: A digital method for collecting patient-, clinician-, observer-, or performance-reported outcome data. Proper design and validation reduce transcription risk and support timely, attributable data capture. |
| eCRF | Electronic Case Report Form: The electronic interface used to capture protocol-required clinical participant data. Its edit checks, field design, role permissions, and completion guidance strongly influence data quality. |
| eCTD | Electronic Common Technical Document: The standardized electronic format used to submit regulated product applications and lifecycle updates. It organizes documents into defined modules, sequences, metadata, and navigation structures. |
| EDC | Electronic Data Capture: A computerized system used to collect, review, query, and manage clinical trial data. Validation, role-based access, edit checks, audit trails, and integrations are key operating considerations. |
| EHS | Environment, Health, and Safety: The management discipline covering occupational safety, environmental compliance, hazardous materials, industrial hygiene, and emergency response. Strong controls are essential in laboratories, chemical plants, and manufacturing facilities. |
| ELISA | Enzyme-Linked Immunosorbent Assay: A plate-based method for detecting or quantifying proteins, antibodies, antigens, or other analytes. It is widely used in bioanalysis, immunogenicity testing, research, and quality-control laboratories. |
| ELN | Electronic Laboratory Notebook: Software for recording experiments, methods, observations, results, and supporting files. Controlled implementations improve searchability, collaboration, intellectual-property records, and data traceability. |
| EM | Environmental Monitoring: Routine measurement of viable microorganisms, nonviable particles, and relevant facility conditions in controlled environments. Trends provide evidence that contamination controls remain effective. |
| EMA | European Medicines Agency: The European Union agency responsible for scientific evaluation, supervision, and safety monitoring of medicines. Its guidelines and procedures influence development, manufacturing, inspections, and clinical research. |
| ePRO | Electronic Patient-Reported Outcome: A digital measure reported directly by a patient without interpretation by another person. Technology providers must ensure usability, validated data capture, security, and reliable handling of missing data. |
| eTMF | Electronic Trial Master File: A computerized repository for the essential documents demonstrating proper trial conduct and data credibility. Completeness, timeliness, metadata, quality review, and inspection readiness are central controls. |
| EU GMP | European Union Good Manufacturing Practice: The European rules and guidance governing manufacture and testing of medicinal products and active substances. They establish expectations for quality systems, facilities, documentation, validation, and batch certification. |
| EudraCT | European Union Drug Regulating Authorities Clinical Trials Database: The legacy European database and numbering system for interventional clinical trials conducted under the former directive. Historical and transitional studies may continue to reference its identifiers and records. |
| F | |
| FACS | Fluorescence-Activated Cell Sorting: A flow-cytometry technique that analyzes fluorescently labeled cells and physically separates selected populations. It is widely used in research, assay development, and specialized analytical services. |
| FAT | Factory Acceptance Test: Testing performed at a supplier’s facility before equipment is shipped. It verifies agreed specifications and functions early enough to correct deficiencies before installation. |
| FDA | Food and Drug Administration: The U.S. authority regulating drugs, biologics, medical products, clinical research, and applicable manufacturing operations. Its approvals, inspections, guidance, and enforcement actions shape provider requirements. |
| FDF | Finished Dosage Form: A completed pharmaceutical presentation, such as a tablet, capsule, vial, or prefilled container, ready for packaging or distribution. The term distinguishes final formulation services from active-substance manufacture. |
| FEI | FDA Establishment Identifier: A unique number assigned by the U.S. regulator to identify a facility associated with regulated activities. It is used in registrations, submissions, inspections, and facility records. |
| FFS | Form-Fill-Seal: An automated packaging process that forms a package, fills it with product, and seals it in an integrated sequence. It can improve throughput and reduce handling in controlled manufacturing operations. |
| FIH | First-in-Human: The first clinical administration of an investigational product to people. Supporting providers must align clinical supply, bioanalysis, safety monitoring, site activation, and regulatory readiness for this milestone. |
| FMD | Falsified Medicines Directive: European legislation establishing measures to prevent falsified medicines from entering the legal supply chain. Contract packagers and manufacturers may support required safety features and serialization controls. |
| FMEA | Failure Modes and Effects Analysis: A structured risk-assessment method that identifies potential failures, their effects, causes, and existing controls. Teams use it to prioritize mitigation in processes, equipment, methods, and technology transfer. |
| FPFV | First Patient, First Visit: The milestone when the first enrolled participant completes the first protocol-defined visit. It is used to track study startup performance and forecast subsequent enrollment activity. |
| FPI | First Patient In: A clinical development milestone marking the first participant’s enrollment or dosing, as defined by the study. It signals the transition from startup into active conduct. |
| FSO | Full-Service Outsourcing: A delivery model in which a provider assumes responsibility for a broad, integrated package of study activities. Governance typically focuses on end-to-end milestones, quality, cost, and vendor coordination. |
| FSP | Functional Service Provider: An outsourcing model in which a provider supplies capacity and expertise for defined functions such as monitoring, data management, biostatistics, or safety. It is often structured around dedicated teams or unit-based pricing. |
| FTE | Full-Time Equivalent: A standardized measure of labor capacity equal to one full-time worker over a defined period. It is commonly used to scope, price, and manage dedicated outsourced teams. |
| FTIR | Fourier Transform Infrared Spectroscopy: An analytical technique that measures infrared absorption to identify materials and characterize molecular bonds. It is used for raw-material identification, contaminant analysis, and research applications. |
| G | |
| GAMP 5 | Good Automated Manufacturing Practice 5: An industry guide for applying a risk-based lifecycle approach to computerized systems used in regulated environments. It helps organizations scale specification, testing, supplier assessment, and operational controls. |
| GC | Gas Chromatography: An analytical separation technique for volatile or derivatized compounds. Pharmaceutical laboratories use it for solvents, impurities, identity testing, and quantitative assays. |
| GC–MS | Gas Chromatography–Mass Spectrometry: A combined technique that separates volatile compounds and identifies or quantifies them by mass. It is valuable for residual-solvent, impurity, extractables, and forensic investigations. |
| GCP | Good Clinical Practice: The ethical and scientific quality standard for designing, conducting, recording, and reporting clinical trials involving human participants. Compliance protects participants and supports credible, acceptable data. |
| GDP | Good Distribution Practice: Quality requirements for storing and transporting medicinal products throughout the supply chain. Controls address authorization, temperature, security, traceability, complaints, returns, and recalls. |
| GDP | Good Documentation Practice: Principles for creating, correcting, reviewing, approving, and retaining clear and reliable regulated records. They apply to paper and electronic documentation across laboratory, manufacturing, and clinical operations. |
| GDPR | General Data Protection Regulation: The European Union framework governing processing and protection of personal data. Clinical research and laboratory providers must address lawful use, transparency, security, data-subject rights, and international transfers. |
| GHS | Globally Harmonized System of Classification and Labelling of Chemicals: An international framework for communicating chemical hazards through classifications, labels, pictograms, and safety data sheets. It supports consistent handling of laboratory and manufacturing chemicals. |
| GLP | Good Laboratory Practice: Quality-system requirements for planning, performing, monitoring, recording, archiving, and reporting regulated nonclinical studies. Compliance supports the reliability and traceability of data submitted to authorities. |
| GMP | Good Manufacturing Practice: The system of regulatory requirements and controls ensuring products are consistently manufactured and tested to appropriate quality standards. It covers personnel, facilities, materials, processes, records, testing, and release. |
| GxP | Good x Practice: An umbrella term for regulated good-practice frameworks, with the variable representing areas such as manufacturing, laboratory, clinical, or distribution activities. It is commonly used when controls span multiple regulated domains. |
| H | |
| HAZOP | Hazard and Operability Study: A structured team review that identifies process hazards and operating problems by examining deviations from design intent. It is especially relevant to chemical processing, utilities, and scale-up projects. |
| HBEL | Health-Based Exposure Limit: A scientifically derived limit used to assess acceptable cross-contamination and occupational exposure. It informs facility segregation, cleaning limits, containment, and risk management for potent compounds. |
| HEPA | High-Efficiency Particulate Air: A filtration classification used to remove very small airborne particles from controlled environments. Filter selection, installation, integrity testing, and airflow design support cleanroom and biosafety performance. |
| HIPAA | Health Insurance Portability and Accountability Act: A U.S. law that includes privacy and security requirements for protected health information. Clinical research providers must determine how these rules apply to sites, data flows, authorizations, and vendors. |
| HPLC | High-Performance Liquid Chromatography: A core analytical technique for separating, identifying, and quantifying components in a sample. It is widely used for assay, purity, impurities, stability, release, and research testing. |
| HPAPI | Highly Potent Active Pharmaceutical Ingredient: An active substance that can produce effects at very low exposure levels and therefore requires enhanced containment. Facility design, industrial hygiene, cleaning, and handling controls are major provider differentiators. |
| HRMS | High-Resolution Mass Spectrometry: Mass spectrometry capable of distinguishing ions with very small mass differences and providing accurate-mass measurements. It supports impurity identification, metabolite analysis, proteomics, and complex sample characterization. |
| HTS | High-Throughput Screening: The automated testing of large numbers of compounds, samples, or biological conditions. Tools providers enable these workflows through instruments, reagents, consumables, robotics, and data systems. |
| HVAC | Heating, Ventilation, and Air Conditioning: Building systems that control temperature, humidity, pressure, filtration, and airflow. Their design and qualification are critical to cleanrooms, laboratories, containment, and product protection. |
| I | |
| IACUC | Institutional Animal Care and Use Committee: A committee that reviews and oversees animal-care and research programs at U.S. institutions. Preclinical providers rely on its protocol review, facility inspection, and welfare oversight processes. |
| IB | Investigator’s Brochure: A compilation of clinical and nonclinical information about an investigational product relevant to its study in humans. It supports investigator understanding of dosing, risks, monitoring, and safe trial conduct. |
| ICF | Informed Consent Form: The document used to communicate trial information and record a participant’s voluntary consent. Development, ethics approval, version control, translation, and site use require careful management. |
| ICH | International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use: A global body that develops harmonized quality, safety, efficacy, and multidisciplinary guidelines. Its standards shape development programs, submissions, manufacturing controls, and clinical operations. |
| ICP–MS | Inductively Coupled Plasma–Mass Spectrometry: A highly sensitive technique for detecting and quantifying elemental impurities and trace metals. It is widely used for compendial testing, raw-material control, and contamination investigations. |
| ICSR | Individual Case Safety Report: A structured report describing one or more suspected adverse reactions experienced by an individual. Safety-service providers process, assess, code, quality-check, and submit these cases within required timelines. |
| IEC | Independent Ethics Committee: A body that reviews clinical research to protect participants’ rights, safety, and well-being. It evaluates protocols, consent materials, investigator information, and study changes. |
| IEC | International Electrotechnical Commission: An organization that publishes international standards for electrical, electronic, and related technologies. Its standards affect laboratory instruments, automation, safety, electromagnetic compatibility, and equipment qualification. |
| IMP | Investigational Medicinal Product: A medicinal product or placebo being tested or used as a reference in a clinical trial. Manufacture, labeling, release, storage, randomization, and distribution require specialized controls. |
| IMPD | Investigational Medicinal Product Dossier: The European technical dossier describing the quality, manufacture, control, nonclinical, and clinical information supporting use of an investigational product. Manufacturing partners frequently contribute its quality documentation. |
| IND | Investigational New Drug: The U.S. regulatory submission and status that permits an investigational drug to be studied in humans. Supporting providers generate development, manufacturing, nonclinical, and clinical information for the application. |
| IPC | In-Process Control: A check or test performed during manufacturing to monitor the process and, where appropriate, adjust it. Results help ensure intermediates and finished products will meet requirements. |
| IQ | Installation Qualification: Documented verification that equipment or a system is installed according to approved specifications and supplier requirements. It confirms components, utilities, calibration, documentation, and installation conditions. |
| IRB | Institutional Review Board: A U.S. committee responsible for ethical review and continuing oversight of human-subject research. Approval is generally required before a site begins participant-facing trial activities. |
| IRT | Interactive Response Technology: A system used for participant randomization, treatment assignment, inventory control, and clinical supply management. Its configuration must align with the protocol and protect treatment blinding. |
| ISO | International Organization for Standardization: An independent organization that develops international standards for quality, laboratories, manufacturing, information security, and other disciplines. Certification or conformance can be important in supplier qualification and customer contracting. |
| ISO/IEC 17025 | General Requirements for the Competence of Testing and Calibration Laboratories: An international standard covering laboratory impartiality, competence, consistent operation, and valid results. Accreditation is especially relevant to independent testing and calibration providers. |
| ISPE | International Society for Pharmaceutical Engineering: A professional organization that publishes technical guidance for pharmaceutical facilities, systems, manufacturing, and technology. Its baseline guides and good-practice guides are widely used by engineering and quality teams. |
| ISR | Incurred Sample Reanalysis: Repeat analysis of selected study samples to assess reproducibility under real sample conditions. It is an important component of regulated bioanalytical method performance assessment. |
| J | |
| JP | Japanese Pharmacopoeia: Japan’s official compendium of pharmaceutical standards and test methods. Manufacturers and laboratories serving the Japanese market use it to establish applicable material and product requirements. |
| K | |
| KRI | Key Risk Indicator: A quantitative measure used to detect elevated or changing risk in clinical trial conduct or other regulated operations. Thresholds and trends help focus oversight, investigation, and mitigation activities. |
| L | |
| LAL | Limulus Amebocyte Lysate: A reagent derived from horseshoe crab blood cells and used to detect bacterial endotoxins. It underpins several compendial test formats used in pharmaceutical and laboratory quality control. |
| LBA | Ligand-Binding Assay: An assay based on specific binding between an analyte and a capture or detection reagent. Bioanalytical laboratories use these methods to quantify large molecules, biomarkers, and immune responses. |
| LC–MS | Liquid Chromatography–Mass Spectrometry: A combined technique that separates sample components before detecting them by mass. It is used for impurity analysis, metabolite identification, bioanalysis, and complex molecular characterization. |
| LC–MS/MS | Liquid Chromatography–Tandem Mass Spectrometry: A highly selective and sensitive analytical platform using sequential mass analysis after chromatographic separation. It is a standard technology for quantitative small-molecule bioanalysis and trace-level testing. |
| LD50 | Median Lethal Dose: The statistically estimated dose expected to cause death in 50 percent of a test population under defined conditions. It is a historical and sometimes still referenced measure of acute toxicity. |
| LIMS | Laboratory Information Management System: Software for managing samples, tests, specifications, workflows, results, instruments, and reports. It supports traceability, laboratory efficiency, data integrity, and quality-control release processes. |
| LLOQ | Lower Limit of Quantification: The lowest analyte concentration that a validated method can measure with acceptable accuracy and precision. It determines the usable lower end of an assay’s quantitative range. |
| LOA | Letter of Authorization: A document permitting a regulator or another party to reference specified confidential information, such as a master file. It enables customers to rely on supplier information without receiving proprietary details. |
| LOD | Limit of Detection: The lowest amount or concentration of an analyte that can be reliably distinguished from background, though not necessarily quantified. It is a key analytical method characteristic. |
| LOQ | Limit of Quantification: The lowest amount or concentration of an analyte that can be measured with acceptable accuracy and precision. It helps define whether a method is suitable for its intended specification or study range. |
| LPI | Last Patient In: The milestone at which the final planned participant is enrolled or randomized into a clinical study. It is used to forecast final visits, database lock, and reporting timelines. |
| LPLV | Last Patient, Last Visit: The milestone when the final participant completes the final protocol-defined visit. It triggers closeout activities, final data cleaning, reconciliations, and preparation for database lock. |
| M | |
| MAA | Marketing Authorisation Application: A European submission requesting permission to market a medicinal product. Manufacturing and research partners contribute quality, nonclinical, clinical, and inspection-readiness information. |
| MACO | Maximum Allowable Carryover: The calculated maximum amount of a previous product residue permitted in a subsequent product. It is used to establish scientifically justified cleaning-validation acceptance limits. |
| MAH | Marketing Authorisation Holder: The legal entity responsible for an authorized medicinal product in a market. Outsourcing agreements must clearly allocate responsibilities between the holder and contracted manufacturers, laboratories, and safety providers. |
| MALDI–TOF | Matrix-Assisted Laser Desorption/Ionization–Time of Flight: A mass-spectrometry technique used to identify microorganisms and characterize biomolecules or polymers. It combines rapid sample analysis with mass-based identification. |
| MBR | Master Batch Record: The approved manufacturing and packaging instructions for a product and batch size. Executed batch records are generated from this controlled master. |
| MedDRA | Medical Dictionary for Regulatory Activities: A standardized international medical terminology used to code adverse events, medical history, indications, and related regulatory information. Consistent coding supports safety analysis and reporting across programs. |
| MES | Manufacturing Execution System: Software that manages and records production activities between enterprise planning and process-control layers. It can enforce workflows, material status, electronic records, genealogy, and exception management. |
| MHRA | Medicines and Healthcare products Regulatory Agency: The United Kingdom authority responsible for regulating medicines, medical products, clinical trials, and applicable facilities. Its inspections and guidance affect providers serving the U.K. market. |
| MIA | Manufacturing and Import Authorisation: An authorization required for specified manufacture or import of medicinal products in the European regulatory system. Its scope defines approved activities, sites, product types, and certification responsibilities. |
| MOQ | Minimum Order Quantity: The smallest quantity a supplier will produce or sell under defined commercial conditions. It affects sourcing, inventory, trial supply, production economics, and obsolescence risk. |
| MRM | Multiple Reaction Monitoring: A tandem mass-spectrometry mode that monitors selected precursor-to-product ion transitions. It provides high selectivity and sensitivity for quantitative bioanalytical methods. |
| MS | Mass Spectrometry: An analytical technique that measures ions according to mass-to-charge ratio. Instrument platforms support identification, quantification, structural characterization, impurity analysis, and biomolecular research. |
| MSA | Master Services Agreement: A framework contract establishing general legal and commercial terms for an ongoing client-provider relationship. Individual projects are typically authorized through separate statements of work. |
| MSAT | Manufacturing Science and Technology: The function that supports process transfer, scale-up, validation, troubleshooting, lifecycle monitoring, and technical improvement. It connects development knowledge with routine manufacturing execution. |
| MTBF | Mean Time Between Failures: A reliability measure estimating average operating time between repairable equipment failures. Instrument and equipment providers use it to assess design reliability and service requirements. |
| MTD | Maximum Tolerated Dose: The highest dose producing an acceptable level of toxicity under specified study conditions. Preclinical and early clinical programs may use it to guide dose selection and safety margins. |
| MTTR | Mean Time to Repair: A maintainability measure estimating the average time needed to restore failed equipment to service. It affects laboratory uptime, service staffing, spare-parts strategy, and customer support performance. |
| N | |
| NCE | New Chemical Entity: A drug substance containing an active moiety not previously approved in the relevant jurisdiction. Development providers may support route design, process development, analytical characterization, and early clinical supply. |
| NCR | Nonconformance Report: A controlled record documenting a material, product, process, or result that fails to meet a requirement. Its investigation and disposition support traceability and quality-system learning. |
| NDA | New Drug Application: The U.S. submission requesting approval to market a new drug. Contract partners contribute manufacturing, analytical, nonclinical, clinical, statistical, and supporting documentation. |
| NDA | Non-Disclosure Agreement: A legal agreement restricting disclosure and use of confidential information exchanged between parties. It protects technical, commercial, clinical, and intellectual-property information during outsourcing discussions and delivery. |
| NGS | Next-Generation Sequencing: High-throughput technologies that sequence many DNA or RNA fragments in parallel. Tools and service providers supply instruments, reagents, library preparation, sequencing operations, and data analysis. |
| NIST | National Institute of Standards and Technology: A U.S. agency that develops measurement standards, reference materials, calibration resources, and technical guidance. Laboratories use its traceable references to support reliable and comparable measurements. |
| NMR | Nuclear Magnetic Resonance: An analytical technique that uses magnetic properties of atomic nuclei to determine molecular structure, identity, purity, and concentration. It is widely used in chemical development and characterization. |
| NOAEL | No Observed Adverse Effect Level: The highest tested exposure at which no treatment-related adverse effect is observed. Toxicology teams use it when evaluating safety margins and supporting initial human-dose calculations. |
| NPI | New Product Introduction: The cross-functional process for transferring a new product into routine operational and commercial supply. It coordinates technical transfer, sourcing, validation, systems, training, capacity, quality, and launch readiness. |
| O | |
| ODM | Operational Data Model: A Clinical Data Interchange Standards Consortium format for exchanging clinical study data, metadata, administrative data, and audit information. It supports interoperability among research technology systems. |
| OEB | Occupational Exposure Band: A category grouping compounds by hazard and required containment level. It guides facility design, equipment selection, work practices, and protective measures when precise exposure limits are unavailable. |
| OECD | Organisation for Economic Co-operation and Development: An intergovernmental organization that publishes internationally recognized test guidelines and principles for nonclinical safety studies. Preclinical providers use these frameworks to support regulatory acceptance across countries. |
| OEE | Overall Equipment Effectiveness: A manufacturing performance measure combining availability, throughput performance, and quality yield. It helps identify losses and improve utilization of constrained production assets. |
| OEL | Occupational Exposure Limit: The maximum acceptable airborne concentration of a substance for workers over a specified period. It drives containment, ventilation, monitoring, protective equipment, and work-practice decisions. |
| OEM | Original Equipment Manufacturer: A company that designs or manufactures equipment or components sold under its own or another company’s brand. Such relationships are common in instruments, consumables, modules, and laboratory automation. |
| OLAW | Office of Laboratory Animal Welfare: A U.S. National Institutes of Health office overseeing compliance with federal policies for animals used in funded research. Applicable preclinical facilities must maintain required assurances and oversight mechanisms. |
| OOS | Out of Specification: A test result that falls outside an approved specification or acceptance criterion. A scientifically sound, documented investigation must determine validity, root cause, impact, and disposition. |
| OOT | Out of Trend: A result or pattern that is unusual relative to historical or expected performance but may remain within specification. Investigation can identify emerging process, method, material, or stability issues. |
| OQ | Operational Qualification: Documented verification that installed equipment or systems operate as intended throughout specified ranges. Testing normally challenges controls, alarms, functions, and operating limits. |
| OSHA | Occupational Safety and Health Administration: The U.S. authority responsible for workplace safety and health requirements. Laboratories and manufacturing facilities must manage applicable chemical, biological, equipment, and employee-protection obligations. |
| OTIF | On Time in Full: A delivery-performance measure tracking whether customers receive the complete required quantity by the promised date. It is a key indicator of planning, production, release, and supply reliability. |
| P | |
| PAT | Process Analytical Technology: A framework for designing, analyzing, and controlling manufacturing through timely measurement of critical attributes and process performance. It supports greater process understanding and real-time control. |
| PBRER | Periodic Benefit-Risk Evaluation Report: A structured post-authorization report evaluating cumulative benefit and safety information for a medicinal product. Pharmacovigilance providers may prepare and maintain it for global reporting obligations. |
| PCR | Polymerase Chain Reaction: A method that amplifies selected DNA sequences for detection or analysis. It underpins a wide range of research, quality-control, sequencing, and molecular-testing workflows. |
| PDA | Parenteral Drug Association: A professional organization that publishes technical reports and best-practice guidance for pharmaceutical manufacturing and quality. Its materials are widely referenced in sterile processing, validation, and contamination control. |
| PDE | Permitted Daily Exposure: A substance-specific daily exposure considered unlikely to cause adverse effects over a lifetime. It is used to establish cleaning limits and assess cross-contamination risk in shared facilities. |
| Ph. Eur. | European Pharmacopoeia: The official European compendium containing legally relevant quality standards for medicines, substances, and pharmaceutical preparations. Contract manufacturers and laboratories apply its monographs and general methods where required. |
| PI | Principal Investigator: The individual responsible for conducting a clinical study at a site. This person oversees participant safety, protocol compliance, delegation, documentation, and the site research team. |
| PIC/S | Pharmaceutical Inspection Co-operation Scheme: A cooperative arrangement among regulatory authorities intended to harmonize pharmaceutical inspection standards and practices. Its guidance influences inspection expectations across many manufacturing jurisdictions. |
| PK | Pharmacokinetics: The study of drug concentrations and movement through the body over time. Clinical and bioanalytical providers generate and analyze these data to characterize exposure and support dosing decisions. |
| PK/PD | Pharmacokinetics/Pharmacodynamics: The integrated analysis of drug exposure and resulting biological or clinical effects. Modeling this relationship supports dose selection, regimen optimization, and development decisions. |
| PM | Preventive Maintenance: Planned servicing performed at defined intervals to reduce equipment failure and sustain performance. Effective scheduling supports uptime, calibration status, product quality, and reliable laboratory operations. |
| PMDA | Pharmaceuticals and Medical Devices Agency: Japan’s agency for product review, safety measures, and regulatory science. Its consultations, reviews, and inspections affect development and manufacturing programs intended for Japan. |
| PPE | Personal Protective Equipment: Clothing or equipment worn to reduce exposure to workplace hazards. Selection is based on chemical, biological, physical, and process risks and complements engineering and procedural controls. |
| PPQ | Process Performance Qualification: Documented demonstration that a commercial manufacturing process can reproducibly produce acceptable product under routine conditions. Successful execution is a key stage of process validation. |
| PQ | Performance Qualification: Documented verification that equipment or a system performs effectively and reproducibly for its intended process under actual or simulated operating conditions. It follows successful installation and operational qualification. |
| PQR | Product Quality Review: A periodic evaluation of batches, deviations, complaints, changes, stability, and process performance. The review confirms consistency and identifies opportunities for corrective action or improvement. |
| PRO | Patient-Reported Outcome: A measurement reported directly by a patient regarding symptoms, functioning, quality of life, or treatment experience. Instrument selection and administration must support reliable endpoint interpretation. |
| PSUR | Periodic Safety Update Report: A recurring regulatory report summarizing worldwide safety information for an authorized product. The terminology remains common, although newer frameworks often use periodic benefit-risk evaluation reporting. |
| PUPSIT | Pre-Use Post-Sterilization Integrity Testing: Integrity testing of a sterilizing-grade filter after sterilization and before it is used for filtration. The practice provides evidence that the filter was not damaged before processing began. |
| PV | Pharmacovigilance: The detection, assessment, understanding, and prevention of adverse effects or other medicine-related problems. Outsourced services include case processing, aggregate reporting, signal management, literature surveillance, and compliance operations. |
| PV | Process Validation: Documented evidence that a manufacturing process can consistently deliver output meeting predetermined quality requirements. It spans process design, qualification, and ongoing verification throughout the lifecycle. |
| PW | Purified Water: Compendial-quality water used for pharmaceutical processing, cleaning, and laboratory applications where water for injection is not required. Generation, storage, distribution, sanitization, and monitoring must remain controlled. |
| Q | |
| QA | Quality Assurance: The independent and systematic activities that provide confidence regulated work will meet applicable requirements. Responsibilities commonly include quality systems, audits, document control, investigations, training, and oversight. |
| QbD | Quality by Design: A systematic development approach that begins with predefined objectives and emphasizes product and process understanding with risk-based control. It supports robust methods, formulations, and manufacturing processes. |
| QC | Quality Control: The sampling, testing, review, and related operational activities used to verify materials and products meet specifications. Independent laboratory controls support batch release and stability decisions. |
| QMS | Quality Management System: The integrated governance, procedures, responsibilities, records, and improvement mechanisms used to manage quality. Its effectiveness is central to regulatory compliance and client confidence. |
| QP | Qualified Person: A legally recognized professional responsible for certifying certain medicinal-product batches before release in Europe. Contractual arrangements must provide sufficient oversight, documentation, and supply-chain assurance for certification. |
| qPCR | Quantitative Polymerase Chain Reaction: A method that monitors DNA amplification in real time to quantify target sequences. It is used in research, assay development, microbial testing, and molecular quality-control applications. |
| QPPV | Qualified Person Responsible for Pharmacovigilance: The individual with defined responsibility for maintaining a marketing authorization holder’s European safety system. Outsourced arrangements must preserve this person’s authority, access, and oversight. |
| QRM | Quality Risk Management: A systematic process for assessing, controlling, communicating, and reviewing risks to product quality. It helps focus controls and resources according to scientific knowledge and potential impact. |
| QTA | Quality/Technical Agreement: A contract that allocates quality and technical responsibilities between a client and service provider. It addresses areas such as deviations, changes, testing, release, audits, records, complaints, and regulatory communication. |
| QTL | Quality Tolerance Limit: A trial-level threshold for a parameter whose deviation may indicate systematic issues affecting participant protection or result reliability. Exceedances require evaluation and appropriate reporting under risk-based quality management. |
| R | |
| RABS | Restricted Access Barrier System: A physical and aerodynamic barrier that separates an aseptic processing zone from operators while allowing controlled interventions. It reduces contamination risk compared with conventional open cleanroom processing. |
| RBM | Risk-Based Monitoring: A clinical oversight approach that focuses monitoring activities on critical data, processes, sites, and identified risks. It combines centralized analytics with targeted remote and on-site review. |
| RBQM | Risk-Based Quality Management: A broader clinical quality framework that identifies critical factors, evaluates risks, establishes controls, and monitors performance throughout a study. Monitoring is one component of this lifecycle approach. |
| RCA | Root Cause Analysis: A structured investigation used to identify the underlying causes of a deviation, failure, or recurring problem. Effective analysis supports durable corrective action rather than treatment of symptoms. |
| REACH | Registration, Evaluation, Authorisation and Restriction of Chemicals: The European Union framework controlling manufacture, import, and use of chemical substances. Reagent, instrument, and manufacturing suppliers must understand their obligations and communicate substance information through the supply chain. |
| RFI | Request for Information: A structured inquiry used to gather preliminary information about potential providers, capabilities, capacity, technologies, and compliance. It commonly precedes a formal proposal process. |
| RFP | Request for Proposal: A formal solicitation asking providers to propose a technical, operational, timing, governance, and commercial solution. Responses are central to outsourcing-provider selection and bid defense. |
| RFQ | Request for Quotation: A request focused primarily on pricing and defined commercial terms for a specified scope. It is most effective when technical requirements, volumes, assumptions, and deliverables are already clear. |
| RFT | Right First Time: A quality and operational measure of work completed correctly without deviation, rejection, or rework. It is used to assess batch execution, laboratory performance, documentation, and process robustness. |
| RIM | Regulatory Information Management: The processes and systems used to manage submission content, product registrations, commitments, health-authority correspondence, and regulatory data. Effective management supports global compliance and lifecycle changes. |
| RoHS | Restriction of Hazardous Substances: European requirements limiting specified hazardous materials in electrical and electronic equipment. Laboratory-instrument suppliers must control component declarations, technical evidence, and product compliance. |
| RT-qPCR | Reverse Transcription Quantitative Polymerase Chain Reaction: A method that converts RNA to complementary DNA and quantifies selected sequences during amplification. It is widely used for gene-expression, viral, and molecular research applications. |
| RTSM | Randomization and Trial Supply Management: Technology used to assign participants to treatments and manage investigational-product inventory across sites and depots. It helps maintain blinding while balancing supply availability and waste. |
| RUO | Research Use Only: A labeling designation for products intended for laboratory research rather than clinical diagnostic use. Tools suppliers must align claims, promotion, distribution, and customer communications with that limitation. |
| S | |
| S&OP | Sales and Operations Planning: A cross-functional process that balances demand, capacity, inventory, supply, and financial priorities. It is particularly important where client forecasts, long lead times, and constrained manufacturing assets interact. |
| SAE | Serious Adverse Event: An adverse event meeting criteria such as death, life threat, hospitalization, significant disability, or congenital anomaly. Rapid documentation, assessment, reconciliation, and reporting are critical clinical safety activities. |
| SAL | Sterility Assurance Level: The probability of a viable microorganism remaining on or in a product after sterilization. It is used to define and validate the required effectiveness of sterilization processes. |
| SAP | Statistical Analysis Plan: A prospective document detailing statistical methods, populations, endpoints, handling rules, and planned outputs for a study. Finalization before unblinding reduces analytical bias and ambiguity. |
| SAT | Site Acceptance Test: Testing conducted after equipment is delivered and installed at its operating site. It confirms that transport, installation, utilities, interfaces, and local conditions have not compromised agreed performance. |
| SCADA | Supervisory Control and Data Acquisition: An industrial system for monitoring processes, collecting operational data, and providing supervisory control. Regulated use requires appropriate security, access, audit, backup, and change controls. |
| SDR | Source Data Review: Review of source information to assess protocol compliance, data quality, participant safety, and site processes. It is broader than checking exact transcription between source records and study forms. |
| SDS | Safety Data Sheet: A standardized document communicating a chemical’s hazards, handling precautions, storage, exposure controls, and emergency measures. Laboratories and manufacturing sites rely on it for worker protection and chemical management. |
| SDTM | Study Data Tabulation Model: A Clinical Data Interchange Standards Consortium standard for organizing clinical study data for regulatory submission. It provides consistent domains, variables, terminology, and relationships. |
| SDV | Source Data Verification: Comparison of clinical database entries with original source records to confirm accurate transcription. Risk-based strategies determine which data, participants, and sites require verification. |
| SEC | Size-Exclusion Chromatography: A separation technique that resolves molecules according to hydrodynamic size. It is commonly used to evaluate molecular-weight distributions, aggregates, fragments, and polymers. |
| SEND | Standard for Exchange of Nonclinical Data: A Clinical Data Interchange Standards Consortium model for organizing nonclinical study data. Standardized datasets facilitate regulatory submission, review, and cross-study analysis. |
| SFC | Supercritical Fluid Chromatography: A separation technique using a supercritical fluid, commonly carbon dioxide, as a major mobile-phase component. It is valuable for rapid separations and chiral purification or analysis. |
| SIP | Sterilization in Place: Sterilization of installed processing equipment and piping without disassembly, commonly using clean steam. Validated cycles must demonstrate adequate exposure at the hardest-to-sterilize locations. |
| SIV | Site Initiation Visit: The visit or meeting at which a clinical site is trained and confirmed ready to begin study activities. Readiness includes approvals, staff, facilities, systems, documents, and investigational supplies. |
| SLA | Service-Level Agreement: A documented commitment defining measurable service expectations, response times, availability, or quality levels. It helps clients and providers govern operational performance and escalation. |
| SME | Subject Matter Expert: An individual with specialized knowledge and authority in a technical, scientific, regulatory, or operational area. Such experts support design decisions, investigations, audits, transfers, and client discussions. |
| SMF | Site Master File: A document describing a manufacturing site’s quality system, activities, facilities, personnel, equipment, and operations. Regulators and clients use it to understand the site before or during inspection. |
| SMO | Site Management Organization: A company providing operational support to clinical research sites, such as staffing, recruitment, startup, administration, and data coordination. It can serve as an intermediary between sites, sponsors, and research providers. |
| SOP | Standard Operating Procedure: An approved instruction describing how a recurring activity must be performed and documented. Procedures translate regulatory and quality requirements into consistent operating practice. |
| SOW | Statement of Work: A contract document defining project scope, deliverables, assumptions, responsibilities, timelines, pricing, and change mechanisms. Clear drafting is essential to outsourcing governance and margin control. |
| SPR | Surface Plasmon Resonance: A label-free optical technique used to measure biomolecular binding, kinetics, affinity, and concentration. It is common in analytical services, assay development, and research instrumentation. |
| SUS | Single-Use System: Disposable process equipment assembled from components such as bags, tubing, connectors, filters, and sensors. It can reduce cleaning and changeover time but requires supplier, integrity, compatibility, and extractables controls. |
| SUSAR | Suspected Unexpected Serious Adverse Reaction: A serious suspected adverse reaction whose nature or severity is not consistent with applicable reference safety information. It may require expedited reporting to authorities, ethics bodies, and investigators. |
| T | |
| TAT | Turnaround Time: The elapsed time required to complete a defined service, test, release, or deliverable. It is a central performance measure for laboratories, clinical operations, manufacturing, and equipment service. |
| TFF | Tangential Flow Filtration: A membrane process in which feed flows parallel to the filter surface while permeate passes through it. It is used for concentration, buffer exchange, clarification, and scalable bioprocessing. |
| TFL | Tables, Figures, and Listings: Standard statistical outputs used to summarize and present clinical study data. They are generated according to the analysis plan and support interpretation, reporting, and submission documents. |
| TK | Toxicokinetics: The assessment of systemic exposure during toxicology studies and its relationship to dose and observed effects. Bioanalytical results help interpret safety findings and exposure margins. |
| TMF | Trial Master File: The collection of essential documents that permits evaluation of a clinical trial’s conduct and the quality of its data. Sponsors and providers share responsibility for completeness, timeliness, quality, and retention. |
| TOC | Total Organic Carbon: A nonspecific measure of organic material in water or on cleaned equipment surfaces. It is widely used for pharmaceutical water monitoring and cleaning-validation testing. |
| TPP | Target Product Profile: A strategic description of the intended product’s indication, population, dosage form, performance, quality, and differentiation. It aligns development and manufacturing decisions with the desired end state. |
| TT | Technology Transfer: The controlled transfer of product, process, analytical, and manufacturing knowledge between development, sites, or organizations. Success depends on complete documentation, gap assessment, training, comparability, and governance. |
| U | |
| UHPLC | Ultra-High-Performance Liquid Chromatography: A liquid-chromatography approach using high pressures and small particles for faster or higher-resolution separations. It is common in analytical development, quality control, and advanced research laboratories. |
| ULT | Ultra-Low Temperature: Storage conditions commonly maintained near minus 80 degrees Celsius for sensitive research and clinical materials. Freezers, monitoring, alarms, backup power, and contingency plans protect stored samples. |
| ULOQ | Upper Limit of Quantification: The highest analyte concentration that a validated method can measure with acceptable accuracy and precision. Samples above this range generally require validated dilution or reanalysis. |
| UPLC | Ultra Performance Liquid Chromatography: A proprietary high-pressure liquid-chromatography platform designed for rapid, high-resolution separations. The term is widely encountered in laboratory instruments, methods, and service offerings. |
| URS | User Requirements Specification: A controlled document defining what equipment, a system, or software must do for its intended users and regulated process. It provides the basis for design review, supplier selection, testing, and acceptance. |
| USP | United States Pharmacopeia: The organization and compendium establishing public quality standards for medicines, ingredients, and related articles in the United States. Manufacturers and laboratories apply relevant monographs and general chapters. |
| USP–NF | United States Pharmacopeia–National Formulary: The combined compendium of official U.S. standards for drug substances, dosage forms, excipients, and related tests. Compliance affects specifications, methods, reference standards, and release testing. |
| UV–Vis | Ultraviolet–Visible Spectroscopy: An analytical technique measuring light absorption in the ultraviolet and visible ranges. Laboratories use it for concentration, identity, kinetics, purity, and routine quantitative testing. |
| V | |
| VHP | Vaporized Hydrogen Peroxide: A gaseous decontamination method used for isolators, rooms, transfer chambers, and equipment. Cycle development must control concentration, exposure, distribution, material compatibility, and aeration. |
| VMP | Validation Master Plan: A high-level document defining an organization’s validation strategy, scope, responsibilities, priorities, and lifecycle approach. It coordinates qualification and validation across facilities, utilities, equipment, processes, methods, and systems. |
| W | |
| WEEE | Waste Electrical and Electronic Equipment: European requirements governing collection, treatment, recovery, and recycling of electrical and electronic waste. Instrument suppliers must address product marking, registration, reporting, and end-of-life responsibilities. |
| WFI | Water for Injection: High-purity compendial water used in manufacture of parenteral products and other critical applications. Generation, storage, distribution, sanitization, and microbial and chemical control are tightly managed. |
| WHO | World Health Organization: A United Nations agency that publishes international guidance and standards for medicines, laboratories, quality, and public health. Its prequalification and manufacturing expectations are important in global supply programs. |
| X | |
| XRD | X-Ray Diffraction: An analytical technique used to identify and characterize crystalline materials and solid forms. It supports polymorph assessment, raw-material identification, formulation development, and investigations of solid-state changes. |